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Clinical outcome of transcatheter closure of patent 
ductus arteriosus in small children weighing 10 kg or less
Purpose: Transcatheter closure has become an effective therapy in 
most patients with patent ductus arteriosus (PDA). However, there 
are difficulties in transcatheter closure of PDA in small children. We 
reviewed clinical outcomes of transcatheter closure of PDA in children 
weighing less than 10 kg in a single center.
Methods: Between January 2003 and December 2009, 314 patients 
with PDA underwent transcatheter closure in our institute. Among 
them, 115 weighed less than 10 kg. All of these patients underwent 
transcatheter closure of PDA using either COOK Detachable Coil®, 
PFM Nit-Occlud®, or Amplatzer duct occluder®. A retrospective 
review of the treatment results and complications was performed.
Results: The mean age of patients was 9.1±5.9 months (median, 
8 months), and mean weight was 7.6±1.8 kg (median, 7.8 kg). The 
mean diameter of PDA was 3.2±1.4 mm (median, 3 mm). Complete 
occlusion occurred in 113 patients (98%). One patient was sent to 
surgery because of a failed attempt at device closure, and another 
patient had a small residual shunt after device placement. The average 
mean length of hospital stay was 3.0±3.3 days, and mean follow-up 
duration was 21.0±19.6 months. There were no major complications 
in any of the patients.
Conclusion: Transcatheter closure of PDA is considered safe and 
efficacious in infants weighing less than 10 kg. With sufficient 
experience and further effort, transcatheter closure of PDA can be 
accepted as the gold standard of treatment for this group of patients.
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Since the first experience of the transcatheter occlusion of PDA 
by Porstmann et al. in 19671), technical improvements over the 
years have increased the proportion of patients who undergo 
successful transcatheter closure2, 3). Despite the advancement in the 
Introduction
Transcatheter closure is widely considered as treatment of 
choice for patients diagnosed with patent ductus arteriosus (PDA). 
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procedure, there are limitations in transcatheter closure of PDA 
in small children. There is the difficulty in advancing the tighter 
curves through the right heart with a large tubular sheath in small 
children4). Left pulmonary artery stenosis due to protrusion of 
device into the left pulmonary artery has been detected with the 
greater frequency in the smaller children5­7). The procedure was 
generally recommended only for children weighing over 7 to 8 kg 
because the size of the patients’ femoral vessel was relatively smaller 
than the size of the required delivery system. In the past when a 
larger device was used, the procedure was only recommended for 
patients weighing over 10 to 12 kg8). We reviewed our experience to 
determine the efficacy and safety of transcatheter PDA closure in 
infants weighing less than 10 kg, with regard to rates of success and 
complications. 
 Materials and methods
1. Subjects 
A total of 314 patients underwent transcatheter occlusion of 
PDA at Severance Cardiovascular Hospital from January, 2003 
to December, 2009. Among them, 115 (37%) patients (male 49, 
female 66), weighing less than 10 kg, were enrolled in this study. 
We retrospectively analyzed medical records, echocardiographic 
findings, angiographic findings, hemodynamic data and follow­up 
results of these patients.
2. Echocardiographic and cardiac catheterization 
parameters
After confirming left to right shunting through the PDA, the size 
of PDA was measured on color Doppler echocardiography. The left 
ventricular end­diastolic dimension (LVEDD) was measured in 
each patient on M­mode echocardiogram. Hemodynamic studies 
were performed, and the ratio of pulmonary blood flow to systemic 
flow (Qp/Qs ratio) was obtained in each patient during cardiac 
catheterization. Aortograms were obtained in the right anterior 
oblique 30 degree and lateral view. The maximum diameter of the 
narrowest portion of the ductus was measured on frozen image and 
balloon occlusion sizing was performed, if needed. The residual 
shunt was identified by aortogram, 10 to 15 minutes after the 
implantation of the device.
3. Follow-up protocol
Chest X­ray and transthoracic echocardiography were conducted 
at 24 hours after the procedure to evaluate the shape and position 
of the device. The patients underwent clinical evaluation and 
echocardiography at 1 week, 1, 3, 6 and 12 months after the 
procedure and then annually thereafter. All patients were followed 
according to this protocol. Major complications investigated during 
the research included failure of device implantation, embolization 
of device, residual shunt, significant obstruction of aortic arch or 
left pulmonary artery, infective endocarditis and massive blood 
loss. Mild narrowing (peak velocity under the 1.5 m/sec) of left 
pulmonary artery or aorta and transient weak arterial pulse were 
regarded as minor complications. A peak velocity over the 1.5 m/
sec of the left pulmonary artery or descending aorta was considered 
as acquired stenosis. The difference in the LVEDD before and after 
PDA closure was evaluated.
4. Statistical analysis
All data are expressed as mean±standard deviation. A P­value less 
than 0.05 was considered as statistically significant. Comparisons 
of mean LVEDD between before and after procedure were done 
using the paired T­test.
Results
1. Characteristics of subjects
The patients’ mean age was 9.1±5.9 months (range: 1­36 
months), 49 were male and 66 were female, the mean weight was 
7.6±1.8 kg (range: 3.2­10 kg). The mean diameter of PDA was 
3.2±1.4 mm (range: 1.2 to 8 mm), the mean pulmonary blood 
flow to systemic flow (Qp/Qs) ratio was 2.0±0.9, and the mean 
fluoroscopic time was 13.4±3.8 minutes. The mean procedure 
time was 48.6±23.0 minutes (range: 12 to 115 minutes) (Table 1). 
The patients who were performed concomitant procedure such 
as percutaneous transluminal angioplasty (PTA) or percutaneous 
pulmonary valve angioplasty (PPV) have also been included in the 
study. PDA was presented as an isolated lesion in 75 (63%) patients, 
associated heart lesions were as follows: ventricular septal defect 
(VSD, n=13), atrial septal defect (ASD, n=11), coarctation of aorta 
(CoA, n=9), congenital aortic valve stenosis (AS, n=3), hypoplastic 
left pulmonary artery (n=3) and endocardial cushion defect (n=1). 
Table 1. Characteristics of the Patients (n=115)
Variables Data†
Age (month)
Male:Female
Body weight (kg)
Diameter of ductus (mm)
Qp/Qs ratio*
Fluoroscopy time (min)
Procedure time (min)
9.1±5.9 (1-36)
               49:66 (1:1.3)
7.6±1.8 (3.2-10)
3.2±1.4 (1.2-8)
2±0.9
13.4±3.8 (8-36)
48.6±23.0 (12-115)
*the ratio to pulmonary blood flow to systemic flow
†mean±SD
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Some patients had one or more comorbidities (Table 2). Four 
patients had Down syndrome.
2. Results of the procedures
Of the 115 patients, the device was successfully deployed in 
114 patients (99%). COOK Detachable Coil® (COOK Medical 
Inc, Bloomington, IN, USA) (n=2, 2%), Nit­Occlud® (PFM AG, 
Cologne, Germany) (n=60, 52%) and Amplatzer duct occluder® 
(ADO, AGA Medical Corp., Plymouth, MN, USA) (n=53, 46%) 
were used (Fig. 1). Coils were favored in cases of a rather small 
ductus, and in cases of moderate to large ductus, ADO was used.
Sixty patients (52%) had increased LVEDD and 41 patients 
showed normalization at 1­week echocardiographic follow­up. The 
LVEDD had decreased from a mean of 31.2±4.7 to 28.8±4.6 mm 
at 1­month follow­up. The mean systolic pulmonary artery pressure 
was 34.6±1.4 mmHg (range: 15 to 85 mmHg). Pulmonary hyper­
tension, evaluated during cardiac catheterization, was defined as 
pulmonary artery systolic pressure more than 40 mmHg9). Thirty­
four patients had pulmonary hypertension. Pulmonary hyper­
tension, evaluated using TR jet pressure and septal configuration 
on echocardiography, regressed in all 34 patients during follow­up. 
Among them, 11 patients had severe pulmonary hypertension with 
pulmonary artery systolic pressure of more than 60 mmHg. The 
clinical characteristics and treatment results of these patients are 
summarizes in Table 3. Most of them presented with large PDA, 
and seven patients had associated heart lesions; 2 had VSD, 2 had 
ASD, 1 had CoA and 1 had AS. Immediately after the procedure, 
5 patients showed normalization of pulmonary artery pressure. 
Five patients showed normalization of pulmonary artery pressure 
at 1­month echocardiographic follow­up and the remaining patient 
showed normalization at 3­month follow­up.
Table 2. Associated Heart Lesions (n=42)
Associated heart lesions
Ventricular septal defect
Atrial septal defect
Coarctation of aorta
Congenital aortic valve stenosis
Hypoplastic left pulmonary artery
13 (11%)
11 (10%)
  9 (  8%)
  3 (  3%)
  3 (  3%)
Fig. 1. A) Aortograms in the lateral view after implantation of COOK Detachable Coil®. B) Aortograms after implantation 
of PFM Nit-Occlud®. C) Aortogram following implantation of a 10/8 mm Amplatzer duct occluder® shows a residual 
shunt through the device.
Table 3. Clinical Data of Patients who had Severe Pulmonary Hypertension (n=11)
Patient
Age 
(month)
Weight
(kg)
PDA size 
(mm)
Qp/Qs Device Comorbidity
PAP 
(pre-closure)
PAP 
(post-closure)
Follow-up duration 
(month)
1
2
3
4
5
6
7
8
9
10
11
8
8
7
4
5
5
4
14
5
7
6
6.5
7.4
8
4.2
4.9
5.9
5.7
10
6.2
6.6
7
6
5
8
8
5
3
8
6.5
6.8
7
4
2.89
1.8
2.92
2.5
2.2
2.9
2.28
2.29
4.06
2.34
3.22
ADO
ADO
ADO
ADO
ADO
ADO
ADO
ADO
ADO
ADO
ADO
None
VSD
None
ASD
AS
None
CoA
CoA 
None
ASD
VSD
60/25 (35)
85/55 (70)
70/40 (55)
65/25 (40)
60/30 (45)
70/35 (55)
70/35 (50)
70/35 (50)
65/35 (50)
80/50 (65)
60/20 (35)
30/10 (20)
50/20 (35)
50/30 (40)
55/20 (35)
40/15 (30)
40/20 (30)
45/15 (30)
40/20 (30)
35/  5 (20)
55/20 (35)
50/15 (30)
59
18
64
34
50
41
23
16
12
  4
  7
Abbreviations: Qp/Qs ratio, the ratio to pulmonary blood flow to systemic flow; PAP, pulmonary artery pressure; ADO, Amplatzer duct occluder®;VSD, 
ventricular septal defect; ASD, atrial septal defect; AS, aortic valve stenosis; CoA, coarctation of aorta
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3. Failure
Failure occurred in a 3­month­old infant weighting 5.8 kg 
with 4 mm ductus. The patient was also diagnosed as atrial septal 
defect and coarctation of aorta. Initially, the 6/4 ADO device 
was successfully deployed in this patient and was observed in the 
intensive care unit. However, position of device was unstable on 
follow­up echocardiography after one day. As a result, the patient 
was then referred for surgery.
4. Complication 
The mean follow­up duration was 21.0±19.6 months (range: 3 
to 82 months). Of the 114 patients with successful deployment 
of a device, residual shunt was noted in one patient at 3­year 
echocardiographic follow­up. The patient was a 3­month­old infant 
weighing 7.7 kg with 3 mm ductus. The PDA was closed using 6× 
5 mm Nit­Occlud®(pfm AG, Köln, Germany). There still remained 
a very small residual shunt of PDA at his last echocardiographic 
follow­up, 3 years after the procedure. There were no complications 
related to vascular access, hemolysis and massive blood loss in any 
of the patient. However, in two patients, after the implantation of 
the ADO, mild narrowing of descending aorta was noted. One 
of the patients, 1 month­old boy, weighing 3.2 kg, underwent 
transcatheter closure using 6/4 mm ADO. A peak velocity on 
Doppler echocardiography after the procedure was 1.5 m/sec, but 
the echocardiography revealed progressive narrowing of the aorta, 
resulting in a peak velocity ranging from 3.0 to 3.8 m/sec during 
follow­up at 2 months. PTA was performed for narrowing of the 
aorta 3 months after the initial intervention. Aortogram showed a 
significant decrease in peak velocity of aorta from 3.8 m/sec to 1.5 
m/sec. The other patient was a 4 month­old girl, weighing 4.2 kg 
with an 8mm duct and the PDA was closed using 6/4 mm ADO. 
After the procedure, on the echocardiography, a peak velocity 
of 2.0 m/sec was seen. On the follow­up echocardiography after 
12 months, a peak velocity of 1.9 m/sec was seen. These patients 
are under close observation at outpatient clinic without further 
intervention so far. Three patients showed mild narrowing of left 
pulmonary artery, but their peak velocity on left pulmonary artery 
only slightly increased (range: 1.3 m/sec to 1.5 m/sec). After the 
procedure, 2 patients had transient weak pulse on femoral artery, 
which was managed by continuous infusion of heparin, and they all 
recovered their femoral artery pulse tension the next day (Table 4).
Discussion
PDA occurs in 5­10% of all congenital heart defects10). Once 
the diagnosis of the uncomplicated PDA is established, closure is 
recommended by surgery or catheter occlusion to avoid pulmonary 
overflow and prevent infective endocarditis10, 11). Transcatheter 
closure of PDA has been the mainstay of treatment in children and 
adults12). Fortescue et al. presented retrospective case series of 1808 
patients with transcatheter closure of PDA in a report published in 
2010. Overall PDA closure rate was 94 percent and major adverse 
events were 1.5 percent11). There have been only a few minor 
complications compared with the initial interventional data13, 14). 
Nevertheless, procedure­associated complications have been still 
described in different age groups, and they are relatively major in 
infants4­6). Information is also inadequate regarding safety and 
feasibility of transcatheter closure in infants15, 16). Few studies have 
investigated their usefulness in children weighing less than 10 kg17, 18).
Our current study is mainly focused on the clinical results in 
using either Nit­Occlud®, ADO or COOK Detachable Coil® for 
the transcatheter closure of PDA in children weighing less than 10 
kg. Completely successful closure of PDA was achieved in 98% of 
the patients19). This confirms the safety of transcatheter closure of 
PDA in children weighing less than 10 kg. In previous report by 
Kim et al.2), mean age of 150 patients was 38 months and mean 
body weight was 15 kg in our center; however, current study 
focused on younger and smaller patients.
The incidence of PDA is higher in premature infants10). Jung20) 
reported that incidence in preterm infants with persistent patency of 
the ductus arteriosus is about 16 times more than full term infants. 
Delayed closure of the hemodynamically significant patent ductus 
arteriosus is related to the development of various morbidity in 
preterm infants21). Transcatheter closure of PDA can be considered 
as treatment option to avoid the risk of surgical ligation in these 
patients22).
The important factors for successful procedure are vascular 
accessibility, morphology of ductus, availability of device, and 
imaging modality. First of all, the vascular accessibility is an 
Table 4. Procedural Complications (n=9/115, 8%)
Complications N (%)
Major complications
Failure of device implantation
Device embolization
Residual shunt > 12 months
Significant obstruction of aorta or pulmonary artery
Infective endocarditis
Massive blood loss
Total events
Minor complications
Mild narrowing of left pulmonary artery
Mild narrowing of descending aorta
Transient weak arterial pulse
Total events
0 (   0%)
1 (0.9%)
1 (0.9%)
0 (   0%)
0 (   0%)
0 (   0%)
2 (1.7%)
3 (2.6%)
2 (1.7%)
2 (1.7%)
7 (   6%)
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important variable. There is a high potential of thrombosis forma­
tion or interruption in femoral vessel related to vascular access, 
because the diameter of the femoral vessel in infants is small. 
Also, a more invasive approach such as cut­down of femoral vessel 
may be necessary during catheterization. Second, in addition 
to measurement of the diameter, the morphology of the ductus 
should also be assessed by echocardiography before procedure is 
performed. With careful regard to anatomic details and cautious 
planning of device deployment, procedural risks can be minimized 
and success rates can be maximized. Third, the miniaturization 
of device is also an important variable. Catheter manipulations 
within the heart have to be minimized to prevent injury and to 
avoid causing arrhythmias and hemodynamic instability. There is 
also the possibility of narrowing of adjacent aorta from protrusion 
of the aortic retention disc3). Further development in device can 
potentially improve the scope of catheter closure for ducts in preterm 
infants. Recently, Amplatzer duct occluder (ADO) II, a new device 
designed by the AGA Medical (Golden Valley, Minnesota) show 
successful PDA closure and decrease the risk in small patients23). 
Finally, the imaging modality is also an important factor. Because it 
is difficult for very small infants to maintain their vital signs such as 
body temperature and respiration without assistance, the procedure 
by the bedside maybe more suitable than at the catheterization 
laboratory. If portable imaging modality can be used during 
procedures, the risk of transcatheter closure for PDA will decrease 
in small infants.
Surgical ligation of PDA remains the treatment of choice in small 
children. Surgical morbidity, cost, and hospital length of stay have 
been decreased by the technique of video­assisted thoracoscopic 
ligation of the PDA24). However, through our current study 
transcatheter closure for PDA of infants has somewhat established 
its safety and efficacy. Carefully selected group of infants may 
be offered transcatheter closure as a treatment option with great 
caution.
With careful planning and improvement of imaging modality, 
transcatheter closure for PDA can be successfully accomplished in 
preterm infants. Furthermore, transcatheter closure of PDA can 
be accepted as the gold standard of treatment in patients of PDA 
weighing less than 10 kg in the near future soon.
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